Prothena Corporate Overview May 6, 2020 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the sufficiency of our cash position to fund advancement of a broad pipeline; the continued advancement of our discovery and preclinical pipeline; our goal of building a neurotherapeutics engine; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935), and its potential as a treatment for Parkinso ...

Prothena Corporate Overview February 12, 2020 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: our potential to advance new targets and candidates, accelerate our pipeline and integrate insights around neurological dysfunction and the biology of misfolded proteins ; the strength of our capital position; the potential of our pipeline; our goal of building a neurotherapeutics engine; the design, proposed mechanism of action and possi ...

Prothena Corporation (NASDAQ:PRTA) Q4 2019 Earnings Conference Call February 12, 2020 4:30 PM ET Company Participants Randy Fawcett - SVP, Finance and Operations Gene Kinney - President, CEO & Director Tran Nguyen - CFO & COO Conference Call Participants Christopher Marai - Nomura Securities Charles Duncan - Cantor Fitzgerald & Co. Michael Yee - Jefferies Bikramjot Singh - RBC Capital Markets Bikramjot Singh - RBC Capital Markets Jay Olson - Oppenheimer Robert Hazlett - BTIG Operator Good afternoon, ladies ...

Prothena Corporate Overview November 5, 2019 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the strength of our capital position; the potential of our pipeline and the potential to accelerate it and reach significant value inflection points; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935), and its potential as a treatment for Parkinson's disease; the design of the Phase 2 PA ...

Prothena Corporate Overview August 6, 2019 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the strength of our capital position; the potential of our pipeline and the potential to accelerate it and reach significant value inflection points; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935), and its potential as a treatment for Parkinson's disease; the design of the Phase 2 PASA ...

Prothena Corporate Overview May 7, 2019 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the strength of our capital position; the potential of our pipeline and the potential to accelerate it and reach significant value inflection points; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935), and its potential as a treatment for Parkinson's disease; the design of the Phase 2 PASADEN ...

Prothena Corporate Overview March 20, 2019 Forward-Looking Statements This overview contains forward-looking statements. These statements relate to, among other things: the strength of our capital position; the potential of our pipeline and the potential to accelerate it and reach significant value inflection points; the design, proposed mechanism of action and possible clinical benefits of prasinezumab (PRX002/RG7935); the design of the Phase 2 PASADENA study of prasinezumab; amounts we might receive under ...

Prothena Corporation PLC (NASDAQ:PRTA) Q4 2018 Earnings Conference Call February 14, 2019 4:30 PM ET Company Participants Ellen Rose - Head, Communications Gene Kinney - President, CEO & Director Radhika Tripuraneni - Chief Development Officer Wagner Zago - Chief Scientific Officer Tran Nguyen - CFO & COO Conference Call Participants Christopher Marai - Nomura Securities Kennen MacKay - RBC Capital Markets Robert Hazlett - BTIG Operator Good day, ladies and gentlemen, and welcome to the Prothena Fourth Quar ...